Associations - ER mutation

BIOMARKER:

ER mutation

Entrez ID:

2099

Related biomarkers:

‹

›

ER mutation ER mutation	Estrogen Receptor Positive Breast Cancer Estrogen Receptor Positive Breast Cancer	bevacizumab + paclitaxel Sensitive: C3 – Early Trials ESMO-BC 2021 - 1 week bevacizumab + paclitaxel Sensitive : C3 ESMO-BC 2021 - 1wk
ER mutation ER mutation	Estrogen Receptor Positive Breast Cancer Estrogen Receptor Positive Breast Cancer	palbociclib Sensitive: B - Late Trials palbociclib Sensitive : B
ER mutation ER mutation	Breast Cancer Breast Cancer	palbociclib Resistant: B - Late Trials palbociclib Resistant : B
ER mutation ER mutation	Hormone Receptor Positive Breast Cancer Hormone Receptor Positive Breast Cancer	exemestane Resistant: B - Late Trials exemestane Resistant : B
ER mutation ER mutation	Estrogen Receptor Positive Breast Cancer Estrogen Receptor Positive Breast Cancer	fulvestrant Sensitive: B - Late Trials fulvestrant Sensitive : B
ER mutation ER mutation	Estrogen Receptor Positive Breast Cancer Estrogen Receptor Positive Breast Cancer	exemestane Resistant: B - Late Trials exemestane Resistant : B
ER mutation ER mutation	Hormone Receptor Positive Breast Cancer Hormone Receptor Positive Breast Cancer	fulvestrant Sensitive: B - Late Trials fulvestrant Sensitive : B
ER mutation ER mutation	HER2 Negative Breast Cancer HER2 Negative Breast Cancer	Aromatase inhibitor + palbociclib Resistant: B - Late Trials Aromatase inhibitor + palbociclib Resistant : B
ER mutation ER mutation	Breast Cancer Breast Cancer	fulvestrant Sensitive: C2 – Inclusion Criteria fulvestrant Sensitive : C2
ER mutation ER mutation	HER2 Negative Breast Cancer HER2 Negative Breast Cancer	palbociclib + PF-05212384 Sensitive: C3 – Early Trials palbociclib + PF-05212384 Sensitive : C3
ER mutation ER mutation	Breast Cancer Breast Cancer	venetoclax Sensitive: C3 – Early Trials venetoclax Sensitive : C3
ER mutation ER mutation	Estrogen Receptor Positive Breast Cancer Estrogen Receptor Positive Breast Cancer	enobosarm Sensitive: C3 – Early Trials enobosarm Sensitive : C3
ER mutation ER mutation	HER2 Negative Breast Cancer HER2 Negative Breast Cancer	SAR439859 Sensitive: C3 – Early Trials SAR439859 Sensitive : C3
ER mutation ER mutation	HER2 Negative Breast Cancer HER2 Negative Breast Cancer	CDK6 inhibitor Resistant: C3 – Early Trials CDK6 inhibitor Resistant : C3
ER mutation ER mutation	HER2 Negative Breast Cancer HER2 Negative Breast Cancer	CDK4 inhibitor Resistant: C3 – Early Trials CDK4 inhibitor Resistant : C3
ER mutation ER mutation	Hormone Receptor Positive Breast Cancer Hormone Receptor Positive Breast Cancer	alpelisib Resistant: C3 – Early Trials alpelisib Resistant : C3
ER mutation ER mutation	HER2 Negative Breast Cancer HER2 Negative Breast Cancer	RAD1901 Sensitive: C3 – Early Trials RAD1901 Sensitive : C3
ER mutation ER mutation	HER2 Negative Breast Cancer HER2 Negative Breast Cancer	G1T48 Sensitive: C4 – Case Studies G1T48 Sensitive : C4
ER mutation ER mutation	Estrogen Receptor Positive Breast Cancer Estrogen Receptor Positive Breast Cancer	RAD1901 Sensitive: D – Preclinical RAD1901 Sensitive : D

VERI is free for non-commercial use, no login needed.

Content on this site is for research purposes only and is not intended to be a substitute for medical advice.

For commercial access, including additional premium features, please contact us.

By using VERI, you are agreeing to our

and

ACCEPT COOKIES

VERI is free for non-commercial use, no login needed.

Content on this site is for research purposes only and is not intended to be a substitute for medical advice.

For commercial access, including additional premium features, please contact us.

By using VERI, you are agreeing to our

and

ACCEPT COOKIES

VERI is free for non-commercial use, no login needed.

Content on this site is for research purposes only and is not intended to be a substitute for medical advice.

For commercial access, including additional premium features, please contact us.

By using VERI, you are agreeing to our

and

ACCEPT COOKIES